Zacks: Analysts Expect Kura Oncology Inc (KURA) Will Post Earnings of -$0.42 Per Share
Analysts expect Kura Oncology Inc (NASDAQ:KURA) to announce ($0.42) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.46). Kura Oncology posted earnings of ($0.37) per share in the same quarter last year, which suggests a negative year over year growth rate of 13.5%. The firm is expected to issue its next earnings report on Monday, March 11th.
According to Zacks, analysts expect that Kura Oncology will report full-year earnings of ($1.72) per share for the current year, with EPS estimates ranging from ($1.76) to ($1.70). For the next financial year, analysts expect that the company will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.73) to ($1.80). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Kura Oncology.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.01.
Shares of KURA traded down $0.75 during mid-day trading on Wednesday, reaching $16.12. The company had a trading volume of 636,251 shares, compared to its average volume of 286,778. The firm has a market cap of $626.09 million, a PE ratio of -10.61 and a beta of 3.16. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $24.02. The company has a quick ratio of 14.76, a current ratio of 14.76 and a debt-to-equity ratio of 0.02.
In other Kura Oncology news, major shareholder Ecor1 Capital Fund Qualified, bought 40,538 shares of Kura Oncology stock in a transaction that occurred on Thursday, December 13th. The shares were acquired at an average price of $13.90 per share, for a total transaction of $563,478.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 15.30% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Voya Investment Management LLC acquired a new position in shares of Kura Oncology during the 2nd quarter valued at $187,000. BlueMountain Capital Management LLC lifted its holdings in shares of Kura Oncology by 2,315.9% during the 3rd quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock valued at $189,000 after acquiring an additional 10,329 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Kura Oncology during the 3rd quarter valued at $217,000. BB&T Securities LLC acquired a new position in shares of Kura Oncology during the 2nd quarter valued at $291,000. Finally, Credit Suisse AG lifted its holdings in shares of Kura Oncology by 36.7% during the 3rd quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock valued at $318,000 after acquiring an additional 4,869 shares in the last quarter. Institutional investors and hedge funds own 79.28% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: LIBOR
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.